@article {2832,
	title = {Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.},
	journal = {Vaccine},
	volume = {31},
	year = {2012},
	month = {2012 Dec 17},
	pages = {109-13},
	abstract = {Vaccination against human papillomavirus (HPV) types 16 and 18 is recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the U.S. Cervical intraepithelial neoplasia (CIN) grade 2 or 3 and adenocarcinoma in situ (CIN2+) are used to monitor HPV vaccine impact on cervical disease. This report describes vaccination status in women diagnosed with CIN2+ and examines HPV vaccine impact on HPV 16/18-related CIN2+.},
	keywords = {Adolescent, Adult, Cervical Intraepithelial Neoplasia, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Papillomaviridae, Papillomavirus Vaccines, Uterine Cervical Diseases, Young Adult},
	issn = {1873-2518},
	doi = {10.1002/cncr.28038},
	author = {Powell, Suzanne E and Hariri, Susan and Steinau, Martin and Bauer, Heidi M and Bennett, Nancy M and Bloch, Karen C and Niccolai, Linda M and Schafer, Sean and Unger, Elizabeth R and Markowitz, Lauri E}
}
